128 filings
8-K
OBSVF
ObsEva SA
11 Apr 23
Entry into a Material Definitive Agreement
4:01pm
8-K
OBSVF
ObsEva SA
22 Mar 23
Other Events
5:23pm
8-K
OBSVF
ObsEva SA
15 Mar 23
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
7:30am
8-K
OBSVF
ObsEva SA
13 Mar 23
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
7:05am
8-K
OBSVF
ObsEva SA
1 Mar 23
Entry into a Material Definitive Agreement
8:30am
8-K
fa1idl56di2c it
24 Feb 23
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
9:26am
8-K
6wpvczgf997nq kcn4r
3 Jan 23
Regulation FD Disclosure
8:00am
6-K
hihy kn6swud88
19 Dec 22
ObsEva Announces Dismissal of Moratorium Proceedings
8:30am
6-K
04j8yyqf
14 Dec 22
ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing
7:15am
6-K
59g9e vw9
9 Dec 22
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
7:09am
6-K
io30ueyhvfm
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
au6ppjq7xsk2v5ki01f
22 Nov 22
Consent and Amendment Agreement
7:10am
6-K
2l3sc
26 Oct 22
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of
5:11pm
6-K
tcl61yn9acd8s9dlpg1
13 Oct 22
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China
7:13am
6-K
3uq6v nix
13 Sep 22
ObsEva Announces Progress on Restructuring Initiatives
9:13am
6-K/A
3wd qhxmn
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
wl8h25svrab7yjf
22 Aug 22
ObsEva Receives Nasdaq Non-Compliance Notice
6:08am
6-K
ycn4o8nv56mm3s2ae
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
0nzu 3m1h
1 Aug 22
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
7:21am
6-K
w8ue41
29 Jul 22
ObsEva Announces Management Change
7:06am